Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients

Rautenberg C, Middeke JM, Röllig C, Stelljes M, Gaidzik V, Kriege O, Verbeek M, Koch K, Unglaub JM, Thol F, Krause S, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Wass M, Heuser M, Fransecky L, Chemnitz J, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Kobbe G, Jäger PS, Alakel N, von Bonin M, Sockel K, Hanoun M, Platzbecker U, Holderried TA, Morgner A, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Flossdorf S, Schroeder T, Stölzel F (2025)


Publication Type: Journal article

Publication year: 2025

Journal

Book Volume: 15

Article Number: 60

Journal Issue: 1

DOI: 10.1038/s41408-025-01274-0

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Rautenberg, C., Middeke, J.M., Röllig, C., Stelljes, M., Gaidzik, V., Kriege, O.,... Stölzel, F. (2025). Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients. Blood Cancer Journal, 15(1). https://doi.org/10.1038/s41408-025-01274-0

MLA:

Rautenberg, Christina, et al. "Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients." Blood Cancer Journal 15.1 (2025).

BibTeX: Download